Close
Achema middle east
swop processing & packaging

Pfizer Settles Patent Litigation with Mylan Covering Detrol LA®

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Sapio Sciences and Ultima Genomics Partner to Advance Multi-Omics Research

Partnership delivers global, end-to-end solutions to accelerate genomics research Sapio...

Symeres acquiries DGr Pharma to enhance regulatory expertise and broaden its biopharma capabilities

Symeres, a leading global Contract Research, Development and Manufacturing...

Syntegon delivers strong growth and EBITDA improvements in first half of 2025

Successful growth strategy delivers sales growth in H1...

Pfizer Inc. announced that it has settled its litigation against Mylan Inc. and Mylan Pharmaceuticals Inc. relating to Pfizer’s patents covering Detrol LA® (tolterodine tartrate) extended-release capsules.

As a result of this settlement, and past settlements related to these patents, Pfizer expects generic competition for Detrol LA® to commence in the United States no earlier than January 1, 2014, except in certain limited circumstances, and no later than March 1, 2014.

The terms of the settlement agreement are otherwise confidential. A generic version of Detrol LA® has not been approved to date.

The company indicated that this settlement does not result in any change in its 2012 financial guidance previously updated on August 13, 2012.

DISCLOSURE NOTICE: The information contained in this release is as of September 7, 2012. Pfizer assumes no obligation to update forward-looking statements contained in this release as a result of new information or future events or developments.

 

 

 

Latest stories

Related stories

Sapio Sciences and Ultima Genomics Partner to Advance Multi-Omics Research

Partnership delivers global, end-to-end solutions to accelerate genomics research Sapio...

Symeres acquiries DGr Pharma to enhance regulatory expertise and broaden its biopharma capabilities

Symeres, a leading global Contract Research, Development and Manufacturing...

Syntegon delivers strong growth and EBITDA improvements in first half of 2025

Successful growth strategy delivers sales growth in H1...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »